Episode 3: Therapeutic Antibodies in Transition: Multi-Mechanism Strategies Driving the Next Wave of Innovation

As therapeutic antibodies continue to evolve, researchers are developing innovative strategies to address increasingly complex disease biology. Multi-mechanism therapeutics are emerging as a promising approach, combining complementary biological functions to enhance efficacy, overcome treatment resistance and expand the potential of antibody-based therapies. In Episode 3 of the Therapeutic Antibody Series 2026, we will examine the emerging multi-mechanism strategies shaping the next generation of therapeutic antibodies. The session will explore the biological mechanisms driving these advances and how research tools are supporting target characterization, mechanism-of-action studies and functional validation throughout antibody discovery and development. Sign up for your free place to the whole series by completing the form. Key Learning Objectives: The evolution of therapeutic antibodies from conventional monoclonal antibodies to multi-mechanism therapeutic approaches. Emerging biological strategies driving the next generation of antibody therapeutics. How research tools support target characterization, mechanism-of-action studies and functional validation. Mengtong Cao SinoBiological Dr. Mengtong Cao is a Senior Product Scientist at Sino Biological, specializing in cytokine and drug target product portfolios. She is responsible for product portfolio management, market analysis, and product development evaluation. Prior to joining Sino Biological, Dr. Cao received her Ph.D. in Pharmaceutical and Biomedical Sciences from the University of Georgia. She works closely with research, marketing, and commercial teams to identify emerging research trends and develop high-quality recombinant proteins and related research tools for the life science community.